E-DRUG: MSF and The Union release second edition of DR-TB drugs report
----------------------------------------------------------------------
Medecins Sans Frontieres and the International Union Against Tuberculosis and Lung Disease have today released the second edition of DR-TB Drugs Under the Microscope, a report examining prices, sources and issues surrounding medicines used for treatment of drug-resistant TB (DR-TB).
Download the report here:
http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition
[Please fix link in browser if broken]
With new, faster tools diagnosing more people than ever before, DR-TB is a growing epidemic, requiring an immediate response on how to address the urgent need for treatment scale up. But treatment scale up is hampered by a number of factors, including high prices (the average regimen costs US $4,000 - $6,000) and limited availability of quality-assured DR-TB medicines.
DR-TB Drugs Under the Microscope also looks at recent progress in the drug pipeline, with two completely new compounds - bedaquiline and delamanid - due for approval soon, the first new drugs in close to half a century. How these drugs will be used in treatment regimens - whether they’re added to existing regimes or news ones are devised - is critical in managing DR-TB treatment in the future. The report also looks at the issues surrounding access for DR-TB drugs, with a focus on linezolid and clofazimine.
The second edition of DR-TB Drugs Under the Microscope can be found here:
http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition
[Please fix link in browser if broken]
Joanna Keenan
Press Officer
Medecins Sans Frontieres - Access Campaign
E: joanna.keenan[at]geneva.msf.org
T: twitter.com/joanna_keenan
msfaccess.org
twitter.com/MSF_access
facebook.com/MSFaccess